Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre-Antoine Bonnet

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
European Journal of Medicinal Chemistry|March 28, 2016
New IKK inhibitors: Synthesis of new imidazo[1,2-a]quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitorsGeorges Moarbess, Jean-François Guichou, Stéphanie Paniagua-Gayraud, et al.
Bioorganic & Medicinal Chemistry|February 26, 2004
Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitorsCarine Deleuze-Masquéfa, Grégori Gerebtzoff, Guy Subra, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 27, 2009
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanomaSonia Khier, Carine Deleuze-Masquéfa, Georges Moarbess, et al.
European Journal of Medicinal Chemistry|December 14, 2020
Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of actionCindy Patinote, Carine Deleuze-Masquéfa, Kamel Hadj Kaddour, et al.
Journal of Medicinal Chemistry|July 9, 2019
Novel and Selective TLR7 Antagonists among the Imidazo[1,2-<i>a</i>]pyrazines, Imidazo[1,5-<i>a</i>]quinoxalines, and Pyrazolo[1,5-<i>a</i>]quinoxalines SeriesNour Bou Karroum, Georges Moarbess, Jean-François Guichou, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2010
Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomasSonia Khier, Florence Gattacceca, Safia El Messaoudi, et al.
Biomedicines|June 27, 2024
Imiquimod Reverses Chronic Toxoplasmosis-Associated Behavioral and Neurocognitive Anomalies in a Rat ModelShaymaa Itani, Maguy Hamie, Reem El Jammal, et al.
Biomolecules|May 28, 2025
The Novel Imiqualine EAPB02303 Is a Potent Drug for Treating Acute Myeloid LeukemiaPerla Makhoul, Rita Hleihel, Shaymaa Itani, et al.
Bioorganic & Medicinal Chemistry|April 21, 2016
New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure-activity relationshipsZahraa Zghaib, Jean-François Guichou, Johanna Vappiani, et al.
Cell Death & Disease|June 9, 2025
Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer modelsKévin Bigot, Cindy Patinote, Véronique Garambois, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
European Journal of Medicinal Chemistry|March 28, 2016
New IKK inhibitors: Synthesis of new imidazo[1,2-a]quinoxaline derivatives using microwave assistance and biological evaluation as IKK inhibitorsGeorges Moarbess, Jean-François Guichou, Stéphanie Paniagua-Gayraud, et al.
Bioorganic & Medicinal Chemistry|February 26, 2004
Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitorsCarine Deleuze-Masquéfa, Grégori Gerebtzoff, Guy Subra, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 27, 2009
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanomaSonia Khier, Carine Deleuze-Masquéfa, Georges Moarbess, et al.
European Journal of Medicinal Chemistry|December 14, 2020
Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of actionCindy Patinote, Carine Deleuze-Masquéfa, Kamel Hadj Kaddour, et al.
Journal of Medicinal Chemistry|July 9, 2019
Novel and Selective TLR7 Antagonists among the Imidazo[1,2-<i>a</i>]pyrazines, Imidazo[1,5-<i>a</i>]quinoxalines, and Pyrazolo[1,5-<i>a</i>]quinoxalines SeriesNour Bou Karroum, Georges Moarbess, Jean-François Guichou, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 28, 2010
Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomasSonia Khier, Florence Gattacceca, Safia El Messaoudi, et al.
Biomedicines|June 27, 2024
Imiquimod Reverses Chronic Toxoplasmosis-Associated Behavioral and Neurocognitive Anomalies in a Rat ModelShaymaa Itani, Maguy Hamie, Reem El Jammal, et al.
Biomolecules|May 28, 2025
The Novel Imiqualine EAPB02303 Is a Potent Drug for Treating Acute Myeloid LeukemiaPerla Makhoul, Rita Hleihel, Shaymaa Itani, et al.
Bioorganic & Medicinal Chemistry|April 21, 2016
New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure-activity relationshipsZahraa Zghaib, Jean-François Guichou, Johanna Vappiani, et al.
Cell Death & Disease|June 9, 2025
Inhibiting microtubule polymerization with EAPB02303, a prodrug activated by catechol-O-methyl transferase, enhances paclitaxel effect in pancreatic cancer modelsKévin Bigot, Cindy Patinote, Véronique Garambois, et al.
Pageof 4